Every Country, Every Family: Time to Act for Group B Streptococcal Disease Worldwide.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 34725691.
- Also identified by DOI 10.1093/cid/ciab859 and PMC identifier 8775655.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The global burden of Group B Streptococcus (GBS) was estimated for 2015 prompting inclusion of GBS as a priority in the Global Meningitis Roadmap. New estimates for the year 2020 and a WHO report analysing the full value of GBS maternal vaccines has been launched to advance evidence based decision making for multiple stakeholders. In this first of a 10-article supplement, we discuss the following (1) gaps in evidence and action, (2) new evidence in this supplement, and (3) what actions can be taken now and key research gaps ahead. We call for investment in the research pipeline, notably description, development, and delivery, in order to accelerate progress and address the large burden of GBS for every family in every country.
Medical subject headings
- Streptococcal Infections
- Vaccines